Results 21 to 30 of about 2,752 (194)

A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study

International Journal of COPD, 2015
Georges Juvelekian,1 Waleed El-Sorougi,2 Chaicharn Pothirat,3 Faisal Yunus,4 Teresita De Guia,5 Han-Pin Kuo,6 Shalma Basu Patnaik,7 Virginia Pilipovic8 1St Georges Hospital University Medical Center, Ashrafieh, Beirut, Lebanon; 2Chest Department ...
Juvelekian G, El-Sorougi W, Pothirat C, Yunus F, De Guia T, Kuo H, Basu Patnaik S, Pilipovic V   +7 more
doaj   +1 more source

Indacaterol for the treatment of chronic obstructive pulmonary disease

Expert Opinion on Pharmacotherapy, 2014
The need for a rapid onset of action and a long duration of the broncholytic effect is the likely reason for the development of new long-acting β2-agonists (LABAs) that are fast acting and have true 24 h duration of action. Indacaterol is the archetype of once-daily LABAs and already marketed as a maintenance therapy in patients with moderate to severe
Matera, M, ROGLIANI, PAOLA, CAZZOLA, MARIO   +2 more
openaire   +5 more sources

Influence of indacaterol on daily physical activity in patients with untreated chronic obstructive pulmonary disease

International Journal of COPD, 2015
Yu Nishijima,1,* Seigo Minami,1,* Suguru Yamamoto,1 Yoshitaka Ogata,1 Taro Koba,1,2 Shinji Futami,1 Kiyoshi Komuta1 1Department of Respiratory Medicine, Osaka Police Hospital, Tennoji-ku, Osaka, Japan; 2Department of Internal Medicine, National Hospital
Nishijima Y, Minami S, Yamamoto S, Ogata Y, Koba T, Futami S, Komuta K   +6 more
doaj   +1 more source

Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trial

International Journal of COPD, 2015
Pierachille Santus,1,2 Dejan Radovanovic,1,2 Silvia Di Marco,3 Vincenzo Valenti,4,5 Rita Raccanelli,1,2 Francesco Blasi,6,7 Stefano Centanni,8,9 Maurizio Bussotti31Department of Health Sciences, University of Milan, 2Pulmonary Rehabilitation Unit ...
Santus P, Radovanovic D, Di Marco S, Valenti V, Raccanelli R, Blasi F, Centanni S, Bussotti M   +7 more
doaj   +1 more source

Efficacy of indacaterol 75 µg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis

International Journal of COPD, 2012
Shannon Cope,1 Matthias Kraemer,2 Jie Zhang,3 Gorana Capkun-Niggli,2 Jeroen P Jansen11MAPI Consultancy, Boston, MA, USA; 2Novartis Pharmaceuticals, Basel, Switzerland; 3Novartis Pharmaceuticals, East Hanover, NJ, USABackground: The purpose of this study ...
Cope S, Kraemer M, Zhang J, Capkun-Niggli G, Jansen JP   +4 more
doaj   +1 more source

Temporal and Partial Reversal of Airflow Limitation in Patients With COPD Treated With Single-Inhaler Long-Acting Dual Bronchodilators. [PDF]

Clin Respir J
Single‐inhaler dual bronchodilator therapy significantly improved FEV1, FEV1/FVC, and other spirometry parameters in patients with COPD. The improvements in FEV1 and FEV1/FVC exhibits different trends. Notably, 21 patients (11.5%) achieved a reversal of the FEV1/FVC ratio to over 70%.
Lu Y, Zhou Y, Xue L, Tian H, Han J, Yang Y, Guo Y, Jiang W, Chen C, Wang L, Song Y.   +10 more
europepmc   +2 more sources

Updates in COPD Management: From Inflammatory Pathways to Targeted Therapies. [PDF]

Eur J Clin Invest
COPD is a heterogeneous disease driven by overlapping neutrophilic and eosinophilic inflammatory pathways. This review highlights the shift from symptom‐based treatment toward phenotype‐ and biomarker‐directed care. Blood eosinophils, FeNO, and IgE predict corticosteroid responsiveness and identify candidates for biologic therapy.
Raman S, Rahman S, Polverino F, Adrish M.   +3 more
europepmc   +2 more sources

Efficacy of tiotropium and indacaterol monotherapy and their combination on dynamic lung hyperinflation in COPD: a random open-label crossover study

International Journal of COPD, 2017
Keisaku Fujimoto,1 Haruna Yamazaki,2 Midori Ura,2 Yoshiaki Kitaguchi3 1Department of Clinical Laboratory Sciences, School of Health Sciences, 2Department of Biomedical Laboratory Science, Graduate School of Medicine, 3First Department of Internal ...
Fujimoto K, Yamazaki H, Ura M, Kitaguchi Y   +3 more
doaj   +1 more source

A Comparison of the Molecular Pharmacological Properties of Current Short, Long, and Ultra-Long-Acting β₂-Agonists Used for Asthma and COPD. [PDF]

Pharmacol Res Perspect
ABSTRACT β‐agonists have been used in asthma for 120 years. There are two recent changes: ultra‐long‐acting agonists for COPD and new asthma guidelines recommending formoterol/ICS inhalers phasing out short‐acting salbutamol inhalers. Few studies directly compare the molecular pharmacological properties of short (salbutamol, terbutaline, fenoterol ...
Proudman RGW, Baker JG.
europepmc   +2 more sources

Indacaterol for chronic obstructive pulmonary disease (COPD)

Drugs of Today, 2010
Indacaterol (Onbrez), previously known as QAB-149-AFA, is a novel ultra-long-acting beta2-adrenoceptor agonist that was recently approved by the European Commission as a new once-daily maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD).
Cazzola M, Proietto A, MATERA, Maria Gabriella   +2 more
openaire   +6 more sources